Literature DB >> 20135719

Involvement of PI3K and ERK1/2 pathways in hepatocyte growth factor-induced cholangiocarcinoma cell invasion.

Apaporn Menakongka1, Tuangporn Suthiphongchai.   

Abstract

AIM: To investigate the role of hepatocyte growth factor (HGF) in cholangiocarcinoma (CCA) cell invasiveness and the mechanisms underlying such cellular responses.
METHODS: Effects of HGF on cell invasion and motility were investigated in two human CCA cell lines, HuCCA-1 and KKU-M213, using Transwell in vitro assay. Levels of proteins of interest and their phosphorylated forms were determined by Western blotting. Localization of E-cadherin was analyzed by immunofluorescence staining and visualized under confocal microscope. Activities of matrix degrading enzymes were determined by zymography.
RESULTS: Both CCA cell lines expressed higher Met levels than the H69 immortalized cholangiocyte cell line. HGF induced invasion and motility of the cell lines and altered E-cadherin from membrane to cytoplasm localization, but did not affect the levels of secreted matrix metalloproteinase (MMP)-2, MMP-9 and urokinase plasminogen activator, key matrix degrading enzymes involved in cell invasion. Concomitantly, HGF stimulated Akt and extracellular signal-regulated kinase (ERK)1/2 phosphorylation but with slightly different kinetic profiles in the two cell lines. Inhibition of the phosphoinositide 3-kinase (PI3K)/Akt pathway by the PI3K inhibitor, LY294002, markedly suppressed HGF-stimulated invasion of both CCA cell lines, and inhibition of the ERK pathway by U0126 suppressed HGF-induced invasion of the KKU-M213 cell line but had a moderate effect on HuCCA-1 cells.
CONCLUSION: These data indicate that HGF promotes CCA cell invasiveness through dys-localization of E-cadherin and induction of cell motility by distinct signaling pathways depending on cell line type.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20135719      PMCID: PMC2817059          DOI: 10.3748/wjg.v16.i6.713

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  46 in total

Review 1.  Met, metastasis, motility and more.

Authors:  Carmen Birchmeier; Walter Birchmeier; Ermanno Gherardi; George F Vande Woude
Journal:  Nat Rev Mol Cell Biol       Date:  2003-12       Impact factor: 94.444

2.  A rapid in vitro assay for quantitating the invasive potential of tumor cells.

Authors:  A Albini; Y Iwamoto; H K Kleinman; G R Martin; S A Aaronson; J M Kozlowski; R N McEwan
Journal:  Cancer Res       Date:  1987-06-15       Impact factor: 12.701

3.  Establishment and characterization of a cholangiocarcinoma cell line from a Thai patient with intrahepatic bile duct cancer.

Authors:  S Sirisinha; T Tengchaisri; S Boonpucknavig; N Prempracha; S Ratanarapee; A Pausawasdi
Journal:  Asian Pac J Allergy Immunol       Date:  1991-12       Impact factor: 2.310

4.  Dependence of metastatic cancer cell invasion on MLCK-catalyzed phosphorylation of myosin regulatory light chain.

Authors:  R Tohtong; K Phattarasakul; A Jiraviriyakul; T Sutthiphongchai
Journal:  Prostate Cancer Prostatic Dis       Date:  2003       Impact factor: 5.554

5.  Effect of hepatocyte growth factor on cadherin-mediated cell-cell adhesion.

Authors:  M Watabe; K Matsumoto; T Nakamura; M Takeichi
Journal:  Cell Struct Funct       Date:  1993-04       Impact factor: 2.212

6.  Tyrosine phosphorylation of beta-catenin and plakoglobin enhanced by hepatocyte growth factor and epidermal growth factor in human carcinoma cells.

Authors:  S Shibamoto; M Hayakawa; K Takeuchi; T Hori; N Oku; K Miyazawa; N Kitamura; M Takeichi; F Ito
Journal:  Cell Adhes Commun       Date:  1994-01

7.  Hepatocyte growth factor modulates motility and invasiveness of ovarian carcinomas via ras mediated pathway.

Authors:  Yousuke Ueoka; Kiyoko Kato; Norio Wake
Journal:  Mol Cell Endocrinol       Date:  2003-04-28       Impact factor: 4.102

8.  Regulation of intracellular pH by immortalized human intrahepatic biliary epithelial cell lines.

Authors:  S A Grubman; R D Perrone; D W Lee; S L Murray; L C Rogers; L I Wolkoff; A E Mulberg; V Cherington; D M Jefferson
Journal:  Am J Physiol       Date:  1994-06

Review 9.  Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation.

Authors:  C J Marshall
Journal:  Cell       Date:  1995-01-27       Impact factor: 41.582

10.  Effect of hepatocyte growth factor on invasion of prostate cancer cell lines.

Authors:  Yasuyoshi Fujiuchi; Osamu Nagakawa; Koji Murakami; Hideki Fuse; Ikuo Saiki
Journal:  Oncol Rep       Date:  2003 Jul-Aug       Impact factor: 3.906

View more
  34 in total

Review 1.  The role of cancer-associated myofibroblasts in intrahepatic cholangiocarcinoma.

Authors:  Alphonse E Sirica
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-11-29       Impact factor: 46.802

2.  ETS-1 protein regulates vascular endothelial growth factor-induced matrix metalloproteinase-9 and matrix metalloproteinase-13 expression in human ovarian carcinoma cell line SKOV-3.

Authors:  Sonali Ghosh; Moitri Basu; Sib Sankar Roy
Journal:  J Biol Chem       Date:  2012-01-23       Impact factor: 5.157

3.  Increased activation of PI3K/AKT signaling pathway is associated with cholangiocarcinoma metastasis and PI3K/mTOR inhibition presents a possible therapeutic strategy.

Authors:  Supak Yothaisong; Hasaya Dokduang; Anchalee Techasen; Nisana Namwat; Puangrat Yongvanit; Vajarabhongsa Bhudhisawasdi; Anucha Puapairoj; Gregory J Riggins; Watcharin Loilome
Journal:  Tumour Biol       Date:  2013-07-06

4.  IL-33 facilitates oncogene-induced cholangiocarcinoma in mice by an interleukin-6-sensitive mechanism.

Authors:  Daisaku Yamada; Sumera Rizvi; Nataliya Razumilava; Steven F Bronk; Jaime I Davila; Mia D Champion; Mitesh J Borad; Jorge A Bezerra; Xin Chen; Gregory J Gores
Journal:  Hepatology       Date:  2015-03-20       Impact factor: 17.425

5.  High expression of ErbB2 contributes to cholangiocarcinoma cell invasion and proliferation through AKT/p70S6K.

Authors:  Warapen Treekitkarnmongkol; Tuangporn Suthiphongchai
Journal:  World J Gastroenterol       Date:  2010-08-28       Impact factor: 5.742

6.  High level of urokinase plasminogen activator contributes to cholangiocarcinoma invasion and metastasis.

Authors:  Parichut Thummarati; Sitsom Wijitburaphat; Aruna Prasopthum; Apaporn Menakongka; Banchob Sripa; Rutaiwan Tohtong; Tuangporn Suthiphongchai
Journal:  World J Gastroenterol       Date:  2012-01-21       Impact factor: 5.742

7.  Epidermal growth factor upregulates Skp2/Cks1 and p27(kip1) in human extrahepatic cholangiocarcinoma cells.

Authors:  Ja-Yeon Kim; Hong Joo Kim; Jung Ho Park; Dong Il Park; Yong Kyun Cho; Chong Il Sohn; Woo Kyu Jeon; Byung Ik Kim; Dong Hoon Kim; Seoung Wan Chae; Jin Hee Sohn
Journal:  World J Gastroenterol       Date:  2014-01-21       Impact factor: 5.742

8.  NK4 gene therapy inhibits HGF/Met-induced growth of human cholangiocarcinoma cells.

Authors:  Xianxiu Ge; Youli Wang; Yun Wang; Quanpeng Li; Hong Yu; Lin Miao
Journal:  Dig Dis Sci       Date:  2013-01-12       Impact factor: 3.199

9.  Effect of brefelamide on HGF-induced survival of 1321N1 human astrocytoma cells.

Authors:  Shigeyoshi Honma; Sachina Takasaka; Takahiro Ishikawa; Takahiro Shibuya; Satoru Mitazaki; Sumiko Abe; Makoto Yoshida
Journal:  In Vitro Cell Dev Biol Anim       Date:  2016-04-29       Impact factor: 2.416

10.  Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA).

Authors:  Jesus M Banales; Vincenzo Cardinale; Guido Carpino; Marco Marzioni; Jesper B Andersen; Pietro Invernizzi; Guro E Lind; Trine Folseraas; Stuart J Forbes; Laura Fouassier; Andreas Geier; Diego F Calvisi; Joachim C Mertens; Michael Trauner; Antonio Benedetti; Luca Maroni; Javier Vaquero; Rocio I R Macias; Chiara Raggi; Maria J Perugorria; Eugenio Gaudio; Kirsten M Boberg; Jose J G Marin; Domenico Alvaro
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-04-20       Impact factor: 46.802

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.